BTYNB IMP1 Inhibitor |
Katalog-Nr.GC42986 |
BTYNB IMP1-Inhibitor ist ein potenter und selektiver Inhibitor der IMP1-Bindung an c-Myc-mRNA (IC50=5 μM). BTYNB IMP1-Inhibitor zeigt SelektivitÄt und Wirksamkeit gegenÜber IMP1-positiven Krebszelllinien. BTYNB IMP1 Inhibitor kann fÜr die Krebsforschung verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 304456-62-0
Sample solution is provided at 25 µL, 10mM.
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). [1] It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Reference:
[1]. Mahapatra, L., Andruska, N., Mao, C., et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10(5), 818-827 (2017).
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *